US2020237685A1PendingUtilityA1

Beta-Hydroxyketones as topical active ingredients for the prevention or treatment of photodermatoses

Assignee: MERCK PATENT GMBHPriority: Nov 27, 2015Filed: Apr 15, 2020Published: Jul 30, 2020

Est. expiryNov 27, 2035(~9.3 yrs left)· nominal 20-yr term from priority

Inventors:Christophe Carola Lilia Heider Marina Lefort Hansjuergen Driller

A61P 17/00A61K 31/12

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to specific β-hydroxyketones of the formula (I) for use in the prevention and/or treatment of photodermatoses and to the use of specific β-hydroxyketones of the formula (I) as active ingredient in typical compositions for the prevention and/or non-therapeutic treatment of photodermatoses, in particular of polymorphic light eruption.

Claims

exact text as granted — not AI-modified

1 .- 8 . (canceled) 
     
     
         9 . A method of inhibiting inflammation, comprising administering to a host in need thereof a compound that is 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)propan-1-one, 1-(4-tert-butylphenyl)-3-hydroxy-3-(4-methoxyphenyl)propan-1-one or a mixture thereof. 
     
     
         10 . A method of inhibiting transcription factor NF-κB, comprising administering to a host in need thereof a compound that is 3-(4-tert-butylphenyl)-3-hydroxy-1-(4-methoxyphenyl)propan-1-one, 1-(4-tert-butylphenyl)-3-hydroxy-3-(4-methoxyphenyl)propan-1-one or a mixture thereof.

Join the waitlist — get patent alerts

Track US2020237685A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.